Series Would be Routinely Recommended Both for Adults 65 Years and Older and for Adults Ages 19 to 64 at Increased Risk for Disease, Such as Those with Certain Underlying Medical Conditions Merck known as MSD outside the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices unanimously voted in favor of updates to pneumococcal .